• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Personalis Inc.

    5/12/26 4:28:07 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Personalis, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    71535D106

    (CUSIP Number)
    05/05/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    71535D106


    1Names of Reporting Persons

    Deep Track Capital, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,760,627.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,760,627.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,760,627.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.51 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP Number(s):
    71535D106


    1Names of Reporting Persons

    Deep Track Biotechnology Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,760,627.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,760,627.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,760,627.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.51 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    71535D106


    1Names of Reporting Persons

    David Kroin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,760,627.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,760,627.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,760,627.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.51 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Personalis, Inc.
    (b)Address of issuer's principal executive offices:

    6600 Dumbarton Circle, Fremont, CA 94555
    Item 2. 
    (a)Name of person filing:

    (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
    (b)Address or principal business office or, if none, residence:

    (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
    (c)Citizenship:

    (i) Delaware (ii) Cayman Islands (iii) United States
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP Number(s):

    71535D106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5,760,627
    (b)Percent of class:

    5.51%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    5,760,627

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    5,760,627

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deep Track Capital, LP
     
    Signature:/s/ David Kroin
    Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
    Date:05/12/2026
     
    Deep Track Biotechnology Master Fund, Ltd.
     
    Signature:/s/ David Kroin
    Name/Title:David Kroin, Director
    Date:05/12/2026
     
    David Kroin
     
    Signature:/s/ David Kroin
    Name/Title:David Kroin
    Date:05/12/2026
    Exhibit Information

    Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of May 12, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 104,631,832 shares outstanding as of February 20, 2026, as reported by the issuer on its 10-K filed with the SEC on February 26, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 12, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

    Get the next $PSNL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PSNL
    SEC Filings

    View All

    SEC Form 144 filed by Personalis Inc.

    144 - Personalis, Inc. (0001527753) (Subject)

    5/29/26 4:25:32 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Personalis Inc.

    144 - Personalis, Inc. (0001527753) (Subject)

    5/28/26 4:38:22 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Inc. filed SEC Form 8-K: Other Events

    8-K - Personalis, Inc. (0001527753) (Filer)

    5/20/26 4:04:03 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hall Christopher M sold $1,102,000 worth of shares (100,000 units at $11.02) as part of a pre-agreed trading plan and exercised 100,000 shares at a strike of $1.61 (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    5/29/26 8:45:05 PM ET
    $PSNL
    Medical Specialities
    Health Care

    CFO AND COO Tachibana Aaron sold $449,292 worth of shares (38,799 units at $11.58) as part of a pre-agreed trading plan and exercised 38,799 shares at a strike of $9.16 (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    5/29/26 8:27:08 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Director Eastham Karin was granted 6,250 shares, increasing direct ownership by 39% to 22,366 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    5/14/26 5:09:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Personalis with a new price target

    Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

    3/17/25 8:20:27 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/5/24 5:15:53 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

    NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. "Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with Ne

    6/2/26 6:00:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

    Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal's single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC). By detecting circulating tumor DNA (c

    5/26/26 6:00:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

    Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer. This decis

    5/20/26 6:00:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l

    3/17/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

    Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

    10/18/23 7:15:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Dr. Kenneth J. Widder Joins Personalis Board of Directors

    Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

    6/13/23 7:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Financials

    Live finance-specific insights

    View All

    Personalis to Announce First Quarter 2026 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly

    4/23/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports Third Quarter 2025 Financial Results

    Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fu

    11/4/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Personalis Inc.

    SC 13G/A - Personalis, Inc. (0001527753) (Subject)

    8/19/24 6:03:38 AM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Personalis Inc.

    SC 13G - Personalis, Inc. (0001527753) (Subject)

    7/26/24 12:56:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Personalis Inc.

    SC 13D/A - Personalis, Inc. (0001527753) (Subject)

    6/28/24 4:01:17 PM ET
    $PSNL
    Medical Specialities
    Health Care